1. Kluin P, Deckert M, Ferry J. Primary diffuse large B-cell lymphoma of the CNS. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Vol. 2, Lyon: IARC Press; 2017:300-302
3. 3. Gospodarowicz M, Bertoni F, Zucca E. Unique aspecits of primary extranodal lymphomas. In: Armitage JO, Mauch PM, Harris NL, Coiffier B, Dalla-Favera R, eds. Non-Hodgkin lymphomas. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2010:540-556
4. Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin's lymphomas. Part 1: gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 1997;8:727–737.
6. Sim J, Takayama T, Cho J, et al. Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016: an observational study. Medicine (Baltimore) 2019;98:e17641.
8. Ferreri AJ, Illerhaus G. The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood 2016;127:1642–1649.
9. Ahn JH, Lee HH, Kim TW, et al. Primary central nervous system lymphoma. J Korean Cancer Assoc 1999;31:627–634.
10. Yoon DH, Lee DH, Choi DR, et al. Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. Bone Marrow Transplant 2011;46:105–109.
11. Hyung J, Hong JY, Yoon DH, et al. Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma. Ann Hematol 2019;98:1657–1664.
14. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21:266–272.
15. Levinson SA, MacFate RP. Clinical laboratory diagnosis. Philadelphia: Lea & Febiger, 1961.
16. Ropper AH, Samuels MA, Klein JP. Imaging, electrophysiologic, and laboratory techniques for neurologic diagnosis. In: Ropper AH, Samuels MA, Klein JP, eds. Adams and Victor's Principles of Neurology, 10th. New York: McGraw-Hill Education, 2014.
17. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006;24:5711–5715.
18. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998;16:859–863.
19. Omuro AM, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 2005;62:1595–1600.
20. Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003;21:4151–4156.
21. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000;18:3144–3150.
22. Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 2015;125:1403–1410.
23. Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 2016;3:e217–e227.
24. Ferreri AJM, Holdhoff M, Nayak L, Rubenstein JL. Evolving treatments for primary central nervous system lymphoma. Am Soc Clin Oncol Educ Book 2019;39:454–466.
25. Houillier C, Taillandier L, Dureau S, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol 2019;37:823–833.
26. Khurana A, Micallef IN, LaPlant BR, et al. Outcomes of autologous stem cell transplant consolidation in primary central nervous system lymphoma: a Mayo Clinic experience. Biol Blood Marrow Transplant 2020;26:2217–2222.
27. Cho H, Kim S, Lee K, Park JS, Suh C. Real-world experience of improvement in the survival of lymphoma and myeloma patients with autologous stem cell transplantation over a 25-year period. Korean J Med 2021;96:501–511.
29. Kim N, Lim DH, Yoon SE, Kim SJ, Kim WS. Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy. J Neurooncol 2021;154:207–217.
30. Yoon WS, Park JS, Kim YI, et al. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience. Asia Pac J Clin Oncol 2021;17:123–130.
32. Ahn SY, Kwon SY, Jung SH, et al. Prognostic significance of interim 11C-methionine PET/CT in primary central nervous system lymphoma. Clin Nucl Med 2018;43:e259–e264.